Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Research Coverage Started at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) in a research note issued to investors on Tuesday. The brokerage set a “buy” rating on the stock.

Several other research analysts have also recently commented on the company. Truist Financial raised their target price on Fresenius Medical Care AG & Co. KGaA from $22.00 to $24.00 and gave the stock a “hold” rating in a research report on Thursday, April 13th. HSBC lowered Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “reduce” rating in a research report on Tuesday, March 7th. Deutsche Bank Aktiengesellschaft upgraded Fresenius Medical Care AG & Co. KGaA from a “sell” rating to a “hold” rating in a research report on Friday, April 28th. Finally, Sanford C. Bernstein started coverage on Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, March 7th. They set a “market perform” rating on the stock. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $28.45.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.9 %

Shares of FMS stock opened at $23.20 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a 12 month low of $12.78 and a 12 month high of $31.00. The company has a quick ratio of 0.91, a current ratio of 1.27 and a debt-to-equity ratio of 0.46. The business’s 50 day moving average is $21.36 and its two-hundred day moving average is $18.37. The company has a market cap of $13.61 billion, a PE ratio of 19.33 and a beta of 1.01.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Rating) last announced its quarterly earnings results on Tuesday, February 21st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.22 by $0.22. The company had revenue of $5.10 billion for the quarter, compared to the consensus estimate of $4.85 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 5.80% and a net margin of 3.46%. Equities analysts predict that Fresenius Medical Care AG & Co. KGaA will post 1.13 EPS for the current year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

Several institutional investors have recently bought and sold shares of FMS. CWM LLC lifted its stake in Fresenius Medical Care AG & Co. KGaA by 82.0% in the 3rd quarter. CWM LLC now owns 1,753 shares of the company’s stock valued at $25,000 after acquiring an additional 790 shares in the last quarter. Wipfli Financial Advisors LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 3rd quarter worth approximately $25,000. Sandy Spring Bank bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth approximately $27,000. Clear Street Markets LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth approximately $28,000. Finally, American National Bank bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 1st quarter worth approximately $32,000. Institutional investors own 5.56% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

(Get Rating)

Fresenius Medical Care AG & Co KgaA engages in the provision of products and services for individuals with renal diseases of which regularly undergo dialysis treatment. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management.